From Wikipedia, the free encyclopedia
Monoclonal antibody
Lumiliximab is an IgG1k
monoclonal antibody that targets
CD23 . It acts as an
immunomodulator
[1] and was awarded
orphan drug status and
fast track designation by the FDA.
[2]
It was investigated in Phase II/III
clinical trials for the treatment of
chronic lymphocytic leukemia .
[3]
[4] It has also been studied for use in
allergic asthma . The drug is a
chimeric antibody from
Macaca irus and
Homo sapiens .
[1]
Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by
Biogen .
Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.
[2] Results published from the CLL clinical trial failed to meet primary endpoints.
[5]
References
^
a
b
"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF) . WHO Drug Information . 18 (3). 2004.
^
a
b
"Lumiliximab" . Adis Insight . Springer Nature Switzerland AG.
^ Byrd JC, Kipps TJ, Flinn IW, Castro J, Lin TS, Wierda W, et al. (January 2010).
"Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia" . Blood . 115 (3): 489–95.
doi :
10.1182/blood-2009-08-237727 .
PMC
2810983 .
PMID
19843887 .
^ Clinical trial number
NCT00801060 for "Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)" at
ClinicalTrials.gov
^ Awan FT, Hillmen P, Hellmann A, Robak T, Hughes SG, Trone D, et al. (November 2014).
"A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia" . British Journal of Haematology . 167 (4): 466–77.
doi :
10.1111/bjh.13061 .
hdl :
2318/1577053 .
PMID
25130401 .
S2CID
25789983 .
Intracellular (initiation)
Intracellular (reception)
Extracellular
Unsorted